Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
PublisherNature Publishing Group
MetadataShow full item record
AbstractChromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majority of the WIP1-containing 17q23 amplicons. The 17q23 amplification results in aberrant expression of WIP1 and miR-21, which not only promotes breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1 and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the HER2+ breast cancer cells harboring 17q23 amplification. To overcome the resistance of trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for specific co-delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound reduction of tumor growth. These results demonstrate the great potential of the combined treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast cancers. Copyright 2018, The Author(s).
KeywordHER2+ breast cancer
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85056263984&doi=10.1038%2fs41467-018-07264-0&partnerID=40&md5=315419d8461fdd1a617b80e530bcf373; http://hdl.handle.net/10713/9731
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
- Authors: De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L
- Issue date: 2015 Nov 10
- Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
- Authors: Rodríguez-Serrano F, Mut-Salud N, Cruz-Bustos T, Gomez-Samblas M, Carrasco E, Garrido JM, López-Jaramillo FJ, Santoyo-Gonzalez F, Osuna A
- Issue date: 2016
- Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
- Authors: Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG, Jia LT
- Issue date: 2014 Feb 26
- miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
- Authors: Kim Y, Kim H, Park D, Han M, Lee H, Lee YS, Choe J, Kim YM, Jeoung D
- Issue date: 2016 Mar 1
- The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.
- Authors: Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O
- Issue date: 2013 Jun